DiA Secures FDA Clearance for New AI-Powered Software, Assisting Ultrasound Users Capture High-Quality Images
Summary
“LVivo IQS is the first of DiA’s 9 FDA-approved software solutions that empowers healthcare professionals with real-time feedback to enable the capture of high-quality ultrasound images,” said Hila Goldman-Aslan, CEO & Founder of DiA Imaging Analysis, “By harnessing the power of AI, our full suite of software solutions helps ultrasound users overcome two major challenges in the field – scanning high-quality images and accurately analyzing them. This holistic approach aligns with our mission of leveraging AI to make ultrasound image capture and analysis processes smarter and more accessible." The results demonstrated high agreement between the LVivo IQS AI’s quality score feedback and the ability to obtain clinically interpretable images as evaluated by Cardiologist specializing in echocardiography. “For precise heart diagnosis and treatment, high-quality cardiac ultrasound imaging is necessary in both point-of-care and other settings," said Dr. Lior Fuchs, Senior Intensive Care Physician at Soroka Medical Center in Israel and principal investigator of the LVivo IQS study. "LVivo IQS AI software will assist us in obtaining faster and clearer images to aid our real-time clinical decision-making process.” DiA Imaging Analysis will exhibit its AI software suite at the American College of Cardiology Annual Scientific Session & Expo (ACC) in New Orleans, March 4-6, 2023- booth #1400.
Classifications
AskAI Classifications
LabelsLinked Companies
